– USA, MA – Shorla Oncology, an Irish specialty pharmaceutical company, today announced the appointment of Dennis Purcell as Board Chairman.
“We are thrilled to welcome Dennis to Shorla,” said CEO, Sharon Cunningham. “During his time in the industry, he has invested in, raised capital for, and advised hundreds of life sciences companies. He is among the most distinguished leaders in biotech and his counsel and expertise will be invaluable to us as we scale our regulatory and commercial efforts in the U.S. and beyond.”
As a preeminent leader in the biotech industry, Purcell brings significant experience that will help guide Shorla in bringing its novel oncology products to the U.S. market.
About Dennis Purcell
Dennis Purcell is the Founder of Aisling Capital LLC, a leading life sciences investment firm based in New York City with $1.8 billion in committed capital and a track record of investing and returning capital since 2000. Before Aisling Capital, Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q. Purcell has also served as Director on several biotechnology company boards including Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis, and Xanodyne Pharmaceuticals.
In addition to his new role as Chairman of the Board at Shorla, Purcell currently sits on the Boards of Real Endpoints, Ichnos Pharmaceuticals, Summus Global, and Embera Pharma. He is also an advisor to Better Health, Cellevolve, and xCellerate. Purcell serves as an Executive-in-Residence at Columbia University and as an Endowment Committee member at the University of Delaware, where he also serves on the Pharmaceutical Innovation Board. Purcell is also involved with industry organizations serving on the Executive Committee of the Board of Directors of New York Bio as well as the Investor Advisory Board of the Biotechnology Innovation Organization, where he serves as Co-Chairman.
“It is an honor to be appointed as Chairman of the Board at Shorla Oncology. In just a few short years, the team has evolved into a pre-commercial entity with a promising pipeline and an established presence in both the U.S. and Europe. I look forward to partnering with the team as they continue to grow and scale,” commented Dennis Purcell.
About Shorla Oncology
Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a privately held, Ireland- and U.S.-based specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for women’s, orphan, and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage, or inadequate for the target population. Shorla’s growing portfolio brings accessible, affordable, and life-saving treatments to patients, delivering a major contribution to patient care.
For more information: https://shorlaoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.